Literature DB >> 15748872

Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory deficits in ischemic rats.

Cesario V Borlongan1, Isabel C Sumaya, Donald E Moss.   

Abstract

Methanesulfonyl fluoride (MSF), a highly selective CNS inhibitor of acetylcholinesterase, has been recently demonstrated to promote improvement in cognitive performance in patients with senile dementia of Alzheimer type. Because a similar cognitive impairment may accompany stroke, we investigated in the present study whether treatment with MSF could produce beneficial effects in adult rats subjected to an experimental stroke model. Sprague-Dawley rats received transient 60 min intraluminal occlusion of the right middle cerebral artery (MCAo) and were given i.p. injections of either MSF (1 mg/kg at 24 and 48 h post-MCAo and 0.3 mg/kg thereafter every other day) or the vehicle, peanut oil, for 4 weeks. Behavioral tests and biochemical assays were performed at 28 days post-surgery. MSF treatment produced about 90% inhibition of acetylcholinesterase in the brain. Ischemic animals that received the vehicle displayed significant elevated body swing biased activity (84.8 +/- 10%) and significantly prolonged acquisition (398 +/- 62 s) and shortened retention (79 +/- 26 s) of the passive avoidance task. Interestingly, while the ischemic animals that received the MSF exhibited elevated body swing biased activity (87.7 +/- 8%), they performed significantly better in the passive avoidance task (255 +/- 36 s and 145 +/- 18 s in acquisition and retention) than the vehicle-treated animals. Moreover, whereas brains from both groups of animals revealed similar extent and degree of cerebral infarction, the MSF-treated ischemic animals showed more intense immunoreactivity, as well as a significantly higher number (10-15% increase) of septal choline acetyltransferase-positive cells than the vehicle-treated ischemic animals. These results show that MSF, possibly by preserving a functional cholinergic system, attenuated stroke-induced deficits in a simple learning and memory task.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748872     DOI: 10.1016/j.brainres.2005.01.028

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.

Authors:  Donald E Moss; Ruth G Perez; Haruo Kobayashi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  A regio- and stereoselective Heck-Matsuda process for construction of γ-aryl allylsulfonyl fluorides.

Authors:  Hao-Yong Qin; Houying Gui; Zai-Wei Zhang; Tao Shu; Hua-Li Qin
Journal:  RSC Adv       Date:  2022-07-04       Impact factor: 4.036

Review 3.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

4.  In utero methanesulfonyl fluoride differentially affects learning and maze performance in the absence of long-lasting cholinergic changes in the adult rat.

Authors:  Luis M Carcoba; Miguel Santiago; Donald E Moss; Rafael Cabeza
Journal:  Pharmacol Biochem Behav       Date:  2007-09-18       Impact factor: 3.533

5.  Guanidinoacetate administration increases acetylcholinesterase activity in striatum of rats and impairs retention of an inhibitory avoidance task.

Authors:  Alexandra I Zugno; Lenir O Pereira; Cristiane Mattos; Emilene B S Scherer; Carlos A Netto; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2008-04-24       Impact factor: 3.584

Review 6.  Elevated body swing test after focal cerebral ischemia in rodents: methodological considerations.

Authors:  Edvin Ingberg; Johanna Gudjonsdottir; Elvar Theodorsson; Annette Theodorsson; Jakob O Ström
Journal:  BMC Neurosci       Date:  2015-08-05       Impact factor: 3.288

7.  Influence of Acetylcholinesterase Inhibitors Used in Alzheimer's Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in THP-1 Macrophages under Fluoride-Induced Oxidative Stress.

Authors:  Marta Goschorska; Izabela Gutowska; Irena Baranowska-Bosiacka; Katarzyna Piotrowska; Emilia Metryka; Krzysztof Safranow; Dariusz Chlubek
Journal:  Int J Environ Res Public Health       Date:  2018-12-20       Impact factor: 3.390

8.  Differentiation of Mesenchymal Stem Cells Derived From Human Adipose Tissue Into Cholinergic-like Cells: An in Vitro Study.

Authors:  Davood Sanooghi; Naser Amini; Fereshteh Azedi; Zohreh Bagher; Asghar Parvishan; Abolfazl Lotfi; Nooshin Rashidi; Erfan Lotfi; Forough Azam Sayahpour; Faezeh Faghihi
Journal:  Basic Clin Neurosci       Date:  2021-05-01

9.  A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease.

Authors:  Donald E Moss; Ruggero G Fariello; Jörg Sahlmann; Isabel Sumaya; Federica Pericle; Enrico Braglia
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 10.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.